These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 31181716)

  • 1. Osteoclast-Released Wnt-10b Underlies Cinacalcet Related Bone Improvement in Chronic Kidney Disease.
    Zheng CM; Hsu YH; Wu CC; Lu CL; Liu WC; Zheng JQ; Lin YF; Chiu HW; Chang TJ; Shyu JF; Lu KC
    Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31181716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Effect of Calcimimetics on Osteoclast-Osteoblast Crosslink in Chronic Kidney Disease and Mineral Bone Disease.
    Hung KC; Chang JF; Hsu YH; Hsieh CY; Wu MS; Wu MY; Chiu IJ; Syu RS; Wang TM; Wu CC; Hung LY; Zheng CM; Lu KC
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33218086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Anabolic Effect of Calcitriol with Osteoclast-Derived Wnt 10b Secretion.
    Lu CL; Shyu JF; Wu CC; Hung CF; Liao MT; Liu WC; Zheng CM; Hou YC; Lin YF; Lu KC
    Nutrients; 2018 Aug; 10(9):. PubMed ID: 30149605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Based on Cinacalcet Reduces Oxidative Stress in Hemodialysis Patients with Secondary Hyperparathyroidism.
    Kuczera P; Adamczak M; Machnik G; Okopien B; Wiecek A
    Nephron; 2018; 139(4):286-292. PubMed ID: 29879701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Cinacalcet on the Redox Status of Albumin in Secondary Hyperparathyroidism Patients Receiving Hemodialysis.
    Imafuku T; Tanaka M; Tokunaga K; Miyamura S; Kato H; Tanaka S; Nakano T; Hirata K; Kadowaki D; Maeda H; Matsushita K; Otagiri M; Komaba H; Fukagawa M; Watanabe H; Maruyama T
    Biol Pharm Bull; 2020; 43(10):1583-1590. PubMed ID: 32999168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TGF-β induces Wnt10b in osteoclasts from female mice to enhance coupling to osteoblasts.
    Ota K; Quint P; Ruan M; Pederson L; Westendorf JJ; Khosla S; Oursler MJ
    Endocrinology; 2013 Oct; 154(10):3745-52. PubMed ID: 23861379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cinacalcet Improves Bone Parameters Through Regulation of Osteoclast Endoplasmic Reticulum Stress, Autophagy, and Apoptotic Pathways in Chronic Kidney Disease-Mineral and Bone Disorder.
    Chiu HW; Hou YC; Lu CL; Lu KC; Liu WC; Shyu JF; Chang JF; Zheng CM
    J Bone Miner Res; 2022 Feb; 37(2):215-225. PubMed ID: 34633122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.
    Meng Y; Zhang H; Li Y; Li Q; Zuo L
    Bone; 2014 Jan; 58():168-76. PubMed ID: 24145307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiscale effects of the calcimimetic drug, etelcalcetide on bone health of rats with secondary hyperparathyroidism induced by chronic kidney disease.
    Sharma S; Kumar S; Tomar MS; Chauhan D; Kulkarni C; Rajput S; Sadhukhan S; Porwal K; Guha R; Shrivastava A; Gayen JR; Kumar N; Chattopadhyay N
    Bone; 2024 Aug; 185():117126. PubMed ID: 38777312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of secondary hyperparathyroidism with paricalcitol with or without cinacalcet in hemodialysis patients.
    Zawierucha J; Małyszko J; Małyszko JS; Prystacki T; Marcinkowski W; Dryl-Rydzyńska T
    Pol Arch Intern Med; 2017 Dec; 127(12):840-845. PubMed ID: 29067991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.
    Cozzolino M; Ketteler M; Martin KJ; Sharma A; Goldsmith D; Khan S
    Nephrol Dial Transplant; 2014 Apr; 29(4):899-905. PubMed ID: 24500308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism.
    Susantitaphong P; Vadcharavivad S; Susomboon T; Singhan W; Dumrongpisutikul N; Jakchairoongruang K; Eiam-Ong S; Praditpornsilpa K
    Ren Fail; 2019 Nov; 41(1):326-333. PubMed ID: 31014177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ligand trap of the activin receptor type IIA inhibits osteoclast stimulation of bone remodeling in diabetic mice with chronic kidney disease.
    Sugatani T; Agapova OA; Fang Y; Berman AG; Wallace JM; Malluche HH; Faugere MC; Smith W; Sung V; Hruska KA
    Kidney Int; 2017 Jan; 91(1):86-95. PubMed ID: 27666759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy.
    Sabbagh Y; Graciolli FG; O'Brien S; Tang W; dos Reis LM; Ryan S; Phillips L; Boulanger J; Song W; Bracken C; Liu S; Ledbetter S; Dechow P; Canziani ME; Carvalho AB; Jorgetti V; Moyses RM; Schiavi SC
    J Bone Miner Res; 2012 Aug; 27(8):1757-72. PubMed ID: 22492547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mineral and bone disorders in conventional hemodialysis: Challenges and solutions.
    Hamano T
    Semin Dial; 2018 Nov; 31(6):592-598. PubMed ID: 29900589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease.
    Finch JL; Tokumoto M; Nakamura H; Yao W; Shahnazari M; Lane N; Slatopolsky E
    Am J Physiol Renal Physiol; 2010 Jun; 298(6):F1315-22. PubMed ID: 20200094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of bone metabolism by Wnt signals.
    Kobayashi Y; Uehara S; Udagawa N; Takahashi N
    J Biochem; 2016 Apr; 159(4):387-92. PubMed ID: 26711238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gsα Controls Cortical Bone Quality by Regulating Osteoclast Differentiation via cAMP/PKA and β-Catenin Pathways.
    Ramaswamy G; Kim H; Zhang D; Lounev V; Wu JY; Choi Y; Kaplan FS; Pignolo RJ; Shore EM
    Sci Rep; 2017 Mar; 7():45140. PubMed ID: 28338087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of cinacalcet for the treatment of calciphylaxis in patients with chronic kidney disease: A comprehensive review.
    Deen J; Schaider H
    Australas J Dermatol; 2019 Aug; 60(3):e186-e194. PubMed ID: 30666627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of TGF-β in a mouse model of high turnover renal osteodystrophy.
    Liu S; Song W; Boulanger JH; Tang W; Sabbagh Y; Kelley B; Gotschall R; Ryan S; Phillips L; Malley K; Cao X; Xia TH; Zhen G; Cao X; Ling H; Dechow PC; Bellido TM; Ledbetter SR; Schiavi SC
    J Bone Miner Res; 2014; 29(5):1141-57. PubMed ID: 24166835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.